{"id":2793,"date":"2021-04-19T06:30:00","date_gmt":"2021-04-19T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/"},"modified":"2021-04-19T06:30:00","modified_gmt":"2021-04-19T06:30:00","slug":"forsta-patienten-transplanterad-i-australiensisk-hjartstudie","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/","title":{"rendered":"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie."},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Den f\u00f6rsta patienten i en pr\u00f6varinitierad studie d\u00e4r donerade hj\u00e4rtan transporteras med hj\u00e4lp av XVIVOs teknologi, transplanterades under f\u00f6rsta kvartalet 2021 p\u00e5 The Alfred Hospital (Melbourne, Australien). Studien som kommer att inkludera transplantationscentra i Australien och Nya Zealand, unders\u00f6ker om den nya preservationsteknologin kan f\u00f6rl\u00e4nga transporttiden f\u00f6r donerade hj\u00e4rtan bortom den nuvarande gr\u00e4nsen p\u00e5 fyra timmar med bibeh\u00e5llen h\u00f6g s\u00e4kerhet.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Det utf\u00f6rs cirka 7500 hj\u00e4rttransplantationer i v\u00e4rlden varje \u00e5r. D\u00e5 det donerade hj\u00e4rtat varken har blodfl\u00f6de eller tillg\u00e5ng till syre under transporten fr\u00e5n donator till mottagare medf\u00f6r f\u00f6rl\u00e4ngda transporttider f\u00f6rs\u00e4mrade resultat efter transplantation. Tiden som det donerade hj\u00e4rtat kan f\u00f6rvaras p\u00e5 is utanf\u00f6r kroppen \u00e4r f\u00f6r n\u00e4rvarande begr\u00e4nsat till h\u00f6gst fyra timmar. De skadliga effekterna av att f\u00f6rl\u00e4nga tiden som hj\u00e4rtat \u00e4r utanf\u00f6r kroppen \u00e5terspeglas i en \u00f6kad frekvens av allvarliga komplikationer och nedsatt \u00f6verlevnad efter transplantation.<\/p>\n<p>XVIVOs innovativa preservationsmetod \u00e4r utvecklad av Professor Stig Steen. Den best\u00e5r av en maskin som under transport kontinuerligt f\u00f6rser det vilande, kylda hj\u00e4rtat med cirkulation av en syresatt l\u00f6sning framtagen f\u00f6r \u00e4ndam\u00e5let. En s\u00e4kerhetsstudie som publicerades i Nature Communications i juni 2020 visade att anv\u00e4ndningen av denna teknologi \u00e4r en s\u00e4ker metod f\u00f6r att transportera m\u00e4nskliga hj\u00e4rtan.<br \/>Den australiensiska pr\u00f6varinitierade studien kommer nu att unders\u00f6ka om XVIVOs nya preservationsteknologi s\u00e4kert kan f\u00f6rl\u00e4nga den tid som det donerade hj\u00e4rtat kan vara utanf\u00f6r kroppen fr\u00e5n den nuvarande gr\u00e4nsen p\u00e5 fyra timmar upp till \u00e5tta timmar.<\/p>\n<p>\u201dVi har precis startat v\u00e5r kliniska pr\u00f6vning och det \u00e4r f\u00f6r tidigt att prata om de f\u00f6rsta transplantationerna, men den omfattande prekliniska forskning som vi gjort tillsammans med the Critical Care Research Group vid Prince Charles Hospital (Brisbane, Australien) har visat p\u00e5 potentialen med denna teknik, s\u00e4ger professor David McGiffin, hj\u00e4rtkirurg och ansvarig pr\u00f6vare f\u00f6r studien tillsammans med professor David Kaye, hj\u00e4rtsvikts- och transplantationskardiolog, b\u00e5da vid Alfred Health.<\/p>\n<p>\u201dBrist p\u00e5 donerade hj\u00e4rtan och den nuvarande maximala transporttiden p\u00e5 fyra timmar begr\u00e4nsar f\u00f6r n\u00e4rvarande antalet patienter som erbjuds ett nytt hj\u00e4rta. Om denna studie kan visa en s\u00e4ker f\u00f6rl\u00e4ngning av den tid som det donerade hj\u00e4rtat kan transporteras, kommer det att m\u00f6jligg\u00f6ra en utvidgning av hj\u00e4rttransplantationsprogram till nya geografiska omr\u00e5den, att fler m\u00f6jliga donationer kan ske med bibeh\u00e5llen s\u00e4kerhet och, i f\u00f6rl\u00e4ngningen, att fler patienter kan erbjudas en livr\u00e4ddande transplantation\u201d, s\u00e4ger Dag Andersson, verkst\u00e4llande direkt\u00f6r f\u00f6r XVIVO.<\/p>\n<p>G\u00f6teborg, 19 april 2021<br \/>Dag Andersson, Verkst\u00e4llande direkt\u00f6r<br \/>XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Dag Andersson, VD, +46 31-788 21 50,\u00a0<a target=\"_blank\" href=\"mailto:dag.andersson@xvivoperfusion.com\" rel=\"nofollow noopener\">dag.andersson@xvivoperfusion.com<\/a><br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73-519 21 64,\u00a0<a href=\"mailto:kristoffer.nordstrom@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">kristoffer.nordstrom@xvivoperfusion.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr\/>\n<p>XVIVO Perfusion AB \u00e4r ett medicinteknikbolag som utvecklar l\u00f6sningar och system f\u00f6r att bed\u00f6ma och bevara organ utanf\u00f6r kroppen, och f\u00f6r att selektera anv\u00e4ndbara organ och h\u00e5lla dem i optimal kondition i v\u00e4ntan p\u00e5 transplantation. XVIVO Perfusion AB har sitt huvudkontor i G\u00f6teborg,\u00a0Sverige och ytterligare kontor finns i Lund, Sverige, Groningen,\u00a0Nederl\u00e4nderna och i Denver, USA. XVIVO-aktien \u00e4r noterad p\u00e5 Nasdaq Stockholm och handlas under symbolen XVIVO.<br \/>Mer information finns att l\u00e4sa p\u00e5 hemsidan <a href=\"http:\/\/www.xvivoperfusion.com.\" target=\"_blank\" rel=\"nofollow noopener\">www.xvivoperfusion.com.<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/7a4ba88a-e752-4848-96a9-db08c021e119\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie.pdf\" target=\"_blank\" rel=\"nofollow noopener\">F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie.<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Den f\u00f6rsta patienten i en pr\u00f6varinitierad studie d\u00e4r donerade hj\u00e4rtan transporteras med hj\u00e4lp av XVIVOs teknologi, transplanterades under f\u00f6rsta kvartalet&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2793","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie. - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie. - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Den f\u00f6rsta patienten i en pr\u00f6varinitierad studie d\u00e4r donerade hj\u00e4rtan transporteras med hj\u00e4lp av XVIVOs teknologi, transplanterades under f\u00f6rsta kvartalet...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\\\/\",\"name\":\"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie. - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2021-04-19T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie. - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/","og_locale":"en_US","og_type":"article","og_title":"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie. - XVIVO","og_description":"Den f\u00f6rsta patienten i en pr\u00f6varinitierad studie d\u00e4r donerade hj\u00e4rtan transporteras med hj\u00e4lp av XVIVOs teknologi, transplanterades under f\u00f6rsta kvartalet...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/","name":"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie. - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2021-04-19T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/forsta-patienten-transplanterad-i-australiensisk-hjartstudie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"F\u00f6rsta patienten transplanterad i australiensisk hj\u00e4rtstudie."}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}